New hope for stem cell transplant patients battling serious complication
NCT ID NCT07340723
Summary
This study is testing if adding a drug called ruxolitinib to the standard steroid treatment works better for controlling a serious immune reaction called acute GVHD. It is for adults who have had a stem cell transplant for blood cancer and develop this complication. The goal is to see if the combination improves response rates and survival compared to steroids alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEM CELL TRANSPLANT COMPLICATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.